Prof. Yu Xianjun graduated from Shanghai medical college, Fudan University and now he is the chair of Department of Pancreatic Surgery, Shanghai Cancer Center/ the president of Pancreatic Cancer Institute, Fudan University and the president of Shanghai Pancreatic Cancer Institute. Prof. Xianjun Yu’s clinical practice has an emphasis on pancreatic cancer surgery and focused on the basic and translational research of the pancreatic cancer. The goal of his team includes: 1. Reduce the postoperative pancreatic fistula rate from 15% to 7% by innovating the pancreaticojejunostomy, increase the median survival time by 30% by standardizing the lymphadenectomy and modifying the protocol of the traditional adjuvant treatment. 2. Conduct a pre-operative serum model which would not benefit from the operation with “CEA+/CA125+/CA19-9≥1000U/mL” and reveal the metabolic characteristic and special molecular target of this group. At present, the applicant has hosted “The National Science Fund for Distinguished Young Scholars” and awarded  “National Innovation Leader among Young and Mid-career Talents of Ministry of Science and Technology” in 2017. He was selected as “New 100 Talents of Shanghai Faulty of Health” and “Shanghai Scientific and Technological Venus Project”. He has also won the “Meiji Bioscientific Outstanding Award” and “Gold Medal of Shanghai Invention Award”. As the corresponding author or first author, he has published over 150 SCI papers in the journals such as J Clin Oncol、Gut、Ann Surg、Cell Res、Clin Cancer Res、Cancer Res and so on in the recent 5 years, total IF > 550, highest IF: 28.2. He also has achieved 5 national patents as the first inventor. Many of his achievements have been included in the diagnosis and treatment guideline of pancreatic cancer.

Reserach Focus:

1. Significantly raising the surgery safety and reducing the treatment cost by innovating the pancreaticojejunostomy and developing the new type surgical instruments;

2. Revealing the characteristics of lymphatic metastasis of pancreatic cancer to standardize the lymphadenectomy;

3. Increasing the treatment level by modifying the protocol of the traditional comprehensive treatment;

4. Conducting the clinical research in order to provide the personalized surgical treatment for pancreatic cancer patients by screening out the molecular targets that would predict the early recurrence and metastasis after the surgery to classify the subpopulation of pancreatic cancer patients who would not benefit from the surgery, which lay the foundation of subsequent study of the further clinical translational research.